Rheumatoid arthritis patients get moving, feel less fatigued when using pedometers

Providing rheumatoid arthritis patients with a simple pedometer has shown to increased daily activity and decrease fatigue, according to a study published in Arthritis Care & Research.

Currently, treating fatigue in these patients can be difficult due to the lack of treatment options. In an effort to improve patients' activity and reduce fatigue, researchers tested how wearing a pedometer could affect patient motivation to move more throughout the day.

A total of 88 participants were included in the study. Those in the control group were not given a pedometer. The individuals who did receive one were either given a goal of steps to achieve per day or received no daily targets. Participants filled out a baseline questionnaire and were monitored for activity for one week before beginning the study. Participants were questioned after 10 weeks and  then again at the end of the study at 21 weeks.

Results showed that pedometer participants, regardless if they had a daily step goal or not, increased daily activity and decreased fatigue. Control participants experienced the opposite over time, as their steps decreased and fatigue remained at a plateau.

"Because rheumatoid arthritis medications have only small effects on fatigue, it's important for patients to have other ways to manage their fatigue," said Patricia Katz, PhD, lead author of the study. "These results suggest that something as simple as increasing physical activity by walking can help."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.